KT-474 is a highly active and selective, orally bioavailable IRAK4 degrader being developed for the treatment of toll-like receptor (TLR)/interleukin-1 receptor (IL-1R)-driven immune-inflammatory diseases.

CFT8634 is an oral activity degrader targeting BRD9 extracted from patent WO2021178920A1 compound 174. CFT8634 can be used for the research of synovial sarcoma and SMARCB1-deleted solid tumors.

NX-5948,be also known as BTK-IN-24,is an oral BTK degrader.

XNW34017 is a PROTAC targeting Aurora A. It binds both Aurora A and the E3 ligase CRBN, leading to ubiquitination of Aurora A by CRBN, followed by specific degradation via the ubiquitin-proteasome system (UPS). This results in cell cycle arrest and apoptosis, thereby killing tumor cells.

ZZ7-23-022 (ZZ7) is a selective BRD9 molecule glue degrader. ZZ7-23-022 effectively degrades BRD9 in synovial sarcoma cells, but does not affect cardiomyocytes. ZZ7-23-022 can be used for the research of cancer.

AMX-883 a selective and orally active BRD9 molecular glue degrader that drives differentiation in acute myeloid leukaemia. AMX-883 shows selectivity over all other bromodomain containing proteins and proteome wide. AMX-883 does not employ the commonly used E3 ligases (cereblon, VHL) but instead drives degradation via DCAF16 as a targeted glue. AMX-883 can be used for the study of acute myeloid leukaemia (AML).

MRT-55811 is a first-in-class, highly selective CCNE1-targeting molecular glue degrader that achieves selective targeting of a previously undruggable target.

TNG961 functions as an orally available, selective molecular glue degrader that targets HBS1L. It is intended for the treatment of tumors characterized by FOCAD deficiency.

MRT-8102 is a molecular glue degrader that targets the NEK7 protein for the treatment of NLRP3 inflammasome-mediated inflammatory diseases.

NST-628 is a brain-penetrant molecular glue targeting the MAPK pathway, effectively inhibiting RAF phosphorylation and MEK activation. By binding to RAF, it disrupts the formation of BRAF-CRAF and BRAF-ARAF heterodimers, thereby blocking the RAS-MAPK signaling cascade. NST-628 exhibits potent anti-tumor activity in RAS- and RAF-driven cancers, demonstrating significant efficacy in mutant KRAS, NRAS, BRAF class II/III, and NF1-mutant tumor models.

NEO-811 is a molecular glue degrader specifically directed against ARNT (also known as HIF-1β). It demonstrates potent antitumor activity as a monotherapy in clear cell renal cell carcinoma (ccRCC).

TRI-611 is a highly potent and selective molecular glue degrader targeting ALK, with the ability to cross the blood-brain barrier. It is designed for the treatment of non-small cell lung cancer that tests positive for ALK fusion proteins.

SB-405483 is a specific small-molecule chemical compound used in scientific research as an allosteric ligand for the protein cereblon (CRBN). It is primarily a biochemical tool for studying protein degradation pathways and has potential implications for drug discovery.

MRT-6160 represents a groundbreaking molecular glue degrader designed to selectively target VAV1, achieving its proteasomal degradation with a DC50 value of 7 nM. This innovative compound showcases its unique mechanism and therapeutic potential.

D927 is a molecular glue and promotes glucose uptake in the absence of insulin. D927 also increases the affinity of RAS binding to PI3Kα by ~500-fold. In vivo, D927 mimicks the effects of insulin and rapidly lowers blood glucose concentrations.

PT-179 is a novel orthogonal immunomodulatory drug (IMiD) derivative that selectively binds to CRBN without inducing degradation of off-target proteins. It demonstrates potent activity in degrading proteins fused to SD40, regardless of whether the fusion occurs at the N or C terminus.